BRCA1 and cancer: By contrast, antioxidant treatment (4-hydroxy-2,2,6,6-tetrametylpeperidine-N-oxyl, tempol) suppressed the levels of estrogen-induced oxidative DNA lesions, and significantly delayed the onset of Brca1-deficiency-induced cancer development [115].